HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)

Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
Also Known As:
Heparin, Low Molecular Weight; Heparin, Low-Molecular-Weight; Low Molecular Weight Heparin; LMWH
Networked: 6635 relevant articles (816 outcomes, 1472 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Carrier, Marc: 42 articles (01/2022 - 01/2003)
2. Akl, Elie A: 35 articles (12/2021 - 04/2008)
3. Agnelli, Giancarlo: 29 articles (01/2022 - 07/2002)
4. Di Nisio, Marcello: 29 articles (01/2021 - 05/2004)
5. Ageno, Walter: 25 articles (08/2022 - 01/2001)
6. Middeldorp, Saskia: 25 articles (07/2021 - 05/2008)
7. Lee, Agnes Y Y: 25 articles (01/2021 - 06/2003)
8. Büller, Harry R: 25 articles (12/2020 - 03/2002)
9. Mousa, Shaker A: 24 articles (01/2021 - 01/2002)
10. Barba, Maddalena: 23 articles (12/2021 - 05/2008)

Related Diseases

1. Neoplasms (Cancer)
2. Venous Thromboembolism
3. Venous Thrombosis (Deep-Vein Thrombosis)
4. Thrombosis (Thrombus)
5. Hemorrhage
08/01/2004 - "In very high-risk patients, a higher dose of LMWH may offer increased efficacy without increasing bleeding risk. "
10/01/2003 - "However the optimal LMWH regimen, offering the greatest efficacy with an acceptable risk of bleeding, has not been clearly established with regard to dose and timing of treatment initiation. "
01/01/2019 - " the primary outcome, the incidence of overall VTE after major abdominal or pelvic surgery was 13.2% in the control group compared to 5.3% in the patients receiving out-of-hospital LMWH (Mantel Haentzel (M-H) odds ratio (OR) 0.38, 95% confidence interval (CI) 0.26 to 0.54; I2 = 28%; moderate-quality evidence).For the secondary outcome of all DVT, seven studies, n = 1728, showed prolonged thromboprophylaxis with LMWH to be associated with a statistically significant reduction in the incidence of all DVT (M-H OR 0.39, 95% CI 0.27 to 0.55; I2 = 28%; moderate-quality evidence).We found a similar reduction when analysis was limited to incidence in proximal DVT (M-H OR 0.22, 95% CI 0.10 to 0.47; I2 = 0%; moderate-quality evidence).The incidence of symptomatic VTE was also reduced from 1.0% in the control group to 0.1% in patients receiving prolonged thromboprophylaxis, which approached significance (M-H OR 0.30, 95% CI 0.08 to 1.11; I2 = 0%; moderate-quality evidence).No difference in the incidence of bleeding between the control and LMWH group was found, 2.8% and 3.4%, respectively (M-H OR 1.10, 95% CI 0.67 to 1.81; I2 = 0%; moderate-quality evidence).No difference in mortality between the control and LMWH group was found, 3.8% and 3.9%, respectively (M-H OR 1.15, 95% CI 0.72 to 1.84; moderate-quality evidence).Estimates of heterogeneity ranged between 0% and 28% depending on the analysis, suggesting low or unimportant heterogeneity. "
01/01/2019 - " the primary outcome, the incidence of overall VTE after major abdominal or pelvic surgery was 13.2% in the control group compared to 5.3% in the patients receiving out-of-hospital LMWH (Mantel Haentzel (M-H) odds ratio (OR) 0.38, 95% confidence interval (CI) 0.26 to 0.54; I2 = 28%; moderate-quality evidence).For the secondary outcome of all DVT, seven studies, n = 1728, showed prolonged thromboprophylaxis with LMWH to be associated with a statistically significant reduction in the incidence of all DVT (M-H OR 0.39, 95% CI 0.27 to 0.55; I2 = 28%; moderate-quality evidence).We found a similar reduction when analysis was limited to incidence in proximal DVT (M-H OR 0.22, 95% CI 0.10 to 0.47; I2 = 0%; moderate-quality evidence).The incidence of symptomatic VTE was also reduced from 1.0% in the control group to 0.1% in patients receiving prolonged thromboprophylaxis (M-H OR 0.30, 95% CI 0.08 to 1.11; I2 = 0%; moderate-quality evidence).No difference in the incidence of bleeding between the control and LMWH group was found, 2.8% and 3.4%, respectively (M-H OR 1.10, 95% CI 0.67 to 1.81; I2 = 0%; moderate-quality evidence).No difference in mortality between the control and LMWH group was found, 3.8% and 3.9%, respectively (M-H OR 1.15, 95% CI 0.72 to 1.84; moderate-quality evidence).Estimates of heterogeneity ranged between 0% and 28% depending on the analysis, suggesting low or unimportant heterogeneity. "
11/27/2018 - " the primary outcome, the incidence of overall VTE after major abdominal or pelvic surgery was 13.2% in the control group compared to 5.3% in the patients receiving out-of-hospital LMWH (Mantel Haentzel (M-H) odds ratio (OR) 0.38, 95% confidence interval (CI) 0.26 to 0.54; I2 = 28%; seven studies, n = 1728; moderate-quality evidence).For the secondary outcome of all DVT, seven studies, n = 1728, showed prolonged thromboprophylaxis with LMWH to be associated with a statistically significant reduction in the incidence of all DVT (M-H OR 0.39, 95% CI 0.27 to 0.55; I2 = 28%; moderate-quality evidence).We found a similar reduction when analysis was limited to incidence in proximal DVT (M-H OR 0.22, 95% CI 0.10 to 0.47; I2 = 0%; moderate-quality evidence).The incidence of symptomatic VTE was also reduced from 1.0% in the control group to 0.1% in patients receiving prolonged thromboprophylaxis (M-H OR 0.30, 95% CI 0.08 to 1.11; I2 = 0%; moderate-quality evidence).No difference in the incidence of bleeding between the control and LMWH group was found, 2.8% and 3.4%, respectively (HM-H OR 1.10, 95% CI 0.67 to 1.81; I2 = 0%; seven studies, n = 2239; moderate-quality evidence).Estimates of heterogeneity ranged between 0% and 28% depending on the analysis, suggesting low or unimportant heterogeneity. "

Related Drugs and Biologics

1. Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
2. Heparin (Liquaemin)
3. Anticoagulants
4. Enoxaparin (Lovenox)
5. Warfarin (Coumadin)
6. Aspirin (Acetylsalicylic Acid)
7. Vitamin K
8. Dalteparin (Dalteparin Sodium)
9. Fondaparinux (Arixtra)
10. Tinzaparin (Innohep)

Related Therapies and Procedures

1. Therapeutics
2. Renal Dialysis (Hemodialysis)
3. Secondary Prevention
4. Hip Replacement Arthroplasty (Total Hip Replacement)
5. Drug Therapy (Chemotherapy)